logo

TVTX

Travere Therapeutics·NASDAQ
--
--(--)
--
--(--)
3.76 / 10
Netural

Comprehensive fundamental analysis rates TVTX at 3.8/10, indicating poor fundamentals. Key positives include a Days sales outstanding of 41.17 (ranked in group 1, score 2/3) and an Interest coverage ratio of 15.48 (ranked in group 1, score 2). However, the PB-ROE factor is high at 2.89, placing it in the least favorable quartile (score 0). Revenue and profit metrics show mixed signals, with Total Operating Revenue growing 127.95% YoY but Profit-MV slightly positive. The weighted score is 3.76, confirming a cautious stance on the company's intrinsic value.

Fundamental(3.76)SentimentTechnical

Analysis Checks(9/10)

Revenue-MV
Value-0.48
Score3/3
Weight20.96%
1M Return10.54%
Total operating revenue (YoY growth rate %)
Value127.95
Score2/3
Weight1.79%
1M Return1.11%
Days sales outstanding
Value41.17
Score2/3
Weight1.82%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight16.71%
1M Return8.45%
Net income-Revenue
Value0.04
Score2/3
Weight16.73%
1M Return8.45%
PB-ROE
Value2.89
Score0/3
Weight4.99%
1M Return2.72%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.67%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value127.95
Score2/3
Weight0.69%
1M Return0.43%
Asset-MV
Value-0.50
Score2/3
Weight21.55%
1M Return10.15%
Cash-MV
Value-1.46
Score2/3
Weight16.43%
1M Return8.41%
Is TVTX fundamentally strong?
  • TVTX scores 3.76/10 on fundamentals and holds a Fair valuation at present. Backed by its -42.63% ROE, -20.32% net margin, -30.02 P/E ratio, 36.13 P/B ratio, and 77.51% earnings growth, these metrics solidify its Netural investment rating.